To evaluate the spectrum of comorbidities and complications and its impact on the clinical outcome in hospitalized patients with coronavirus disease 2019 (COVID-19).
Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is a coronavirus with
human infection designated as COVID-19 by the World Health Organization. Bats and birds serve
as the typical coronavirus hosts, with zoonotic spread and a long-documented history of
animal-animal-human transmission.
Since November 2019, the rapid outbreak of coronavirus disease 2019 (COVID-19), which arose
from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has recently
become a public health emergency of international concern. COVID-19 has contributed to an
enormous adverse impact globally.
As of 10 March 2020 there have been 113702 laboratory confirmed cases and 4012 deaths
globally.
According to the latest reports, the clinical manifestations of COVID-19 are heterogeneous.
On admission, 20-51% of patients were reported as having at least one comorbidity, with
diabetes (10-20%), hypertension (10-15%) and other cardiovascular and cerebrovascular
diseases (7-40%) being most common. Previous studies have demonstrated that the presence of
any comorbidity has been associated with a 3.4-fold increased risk of developing acute
respiratory distress syndrome in patients with H7N9 infection. As with influenza, SARS-CoV
and Middle East Respiratory Syndrome coronavirus (MERS-CoV), COVID-19 is more readily
predisposed to respiratory failure and death in susceptible patients.
Although it is well documented that COVID-19 is primarily manifested as a respiratory tract
infection, emerging data indicate that it should be regarded as a systemic disease involving
multiple systems, including cardiovascular, respiratory, gastrointestinal, neurological,
hematopoietic and immune system. Mortality rates of COVID-19 are lower than SARS and Middle
East Respiratory Syndrome (MERS); however, COVID-19 is more lethal than seasonal flu.
Older people and those with comorbidities are at increased risk of death from COVID-19, but
younger people without major underlying diseases may also present with potentially lethal
complications such as fulminant myocarditis and disseminated intravascular coagulopathy
(DIC).
Other: complication
complication co morbidities
Inclusion Criteria:
Patients presented by respiratory symptom and admitted to Assuit university hospitals in
wards and intensive care units due to COVID-19 according to WHO and Egyptian Ministry of
Health and Population (MOH) definitions with positive PCR result.
Exclusion Criteria:
- Negative PCR result for suspicious cases of Covid-19,
- Patients refusing to participate in the study.
Mahmoud Gamal hussein
01004025057
memog919@gmail.com
Gamal Mohamed Rabee
01221729476
Gamalagmy135@gmail.com
Gamal Mohamed Rabee, Proffessor, Study Chair
Assuit university hospital